TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.

Hill, R., Madureira, P.A., Ferreira, B. et al. (12 more authors) (2017) TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nature Communications, 8. 14687.

Abstract

Metadata

Authors/Creators:
  • Hill, R.
  • Madureira, P.A.
  • Ferreira, B.
  • Baptista, I.
  • Machado, S.
  • Colaco, L.
  • dos Santos, M.
  • Liu, N.
  • Dopazo, A.
  • Ugurel, S.
  • Adrienn, A.
  • Kiss-Toth, E.
  • Isbilen, M.
  • Gure, A.O.
  • Link, W.
Copyright, Publisher and Additional Information: © The Authors, 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Keywords: Mechanisms of disease; Melanoma
Dates:
  • Published (online): 9 March 2017
  • Accepted: 23 January 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Cardiovascular Science (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 01 Feb 2017 11:44
Last Modified: 24 Oct 2018 07:28
Published Version: https://doi.org/10.1038/ncomms14687
Status: Published
Publisher: Nature Publishing Group
Refereed: Yes
Identification Number: https://doi.org/10.1038/ncomms14687

Download

Share / Export

Statistics